Sancuso patch approved for nausea and vomiting

Sancuso patch approved for nausea and vomiting
Sancuso patch approved for nausea and vomiting

The FDA has approved Sancuso (granisetron transdermal patch, from ProStrakan) for the prevention of chemotherapy-induced nausea and vomiting (CINV).

This approval was based on a Phase III double-blind study that showed Sancuso was as effective as oral granisetron in achieving complete CINV control. Complete control was defined as no vomiting and/or retching, no more than mild nausea, and no rescue medication from the first dose of Sancuso until 24 hours after the last day of chemotherapy.

For more information call (908) 234-1096 or visit www.prostrakan-usa.com.